APRIL 2023 / ENAMINE & NOSTRUM BIODISCOVERY COLLABORATION
Nostrum Biodiscovery and ENAMINE Join Forces to Develop a Cutting-Edge Search Engine for REAL Space Billion Database and Enhance HTVS Services
Nostrum Biodiscovery, a leading provider of computational drug discovery services, and ENAMINE, a global supplier of chemical building blocks and screening compounds, announce a groundbreaking collaboration for the co-development of a revolutionary search engine tailored for the REAL Space billion database. This partnership aims to deliver unparalleled performance in searching vast chemical spaces while utilizing low computational resources, thus increasing the efficiency and accessibility of drug discovery efforts.
The collaboration will also focus on enhancing High Throughput Virtual Screening (HTVS) services to streamline the drug discovery process. Nostrum Biodiscovery’s state-of-the-art AI-enabled screening platform will take center stage in this effort, boasting the capability to evaluate the entire billion compound collection in just hours. This innovative technology promises to identify potential drug candidates within weeks, significantly accelerating the discovery pipeline.
ENAMINE’s expertise in the rapid and reliable provision of compounds will further strengthen the collaboration, ensuring that researchers have timely access to the vast array of molecules in the REAL Space database. This partnership will facilitate the seamless integration of Nostrum Biodiscovery’s computational prowess with ENAMINE’s extensive compound collection, directly impacting companies interested in using services offered by both partners and ultimately benefiting the global scientific community and accelerating the path to new drug discoveries.
[Victor Guallar, CSO Nostrum Biodiscovery] “We see it every day in our projects, using the REAL Space database with our AI/MM hybrid HTVS platform is a game changer in finding molecules. Our joint venture with ENAMINE demonstrates our commitment to integrating cutting-edge technology and high-quality compound collections to provide the pharmaceutical industry with unparalleled access to resources that expedite drug discovery. We believe that this partnership will serve as a catalyst for innovation, inspiring ventures to explore uncharted territories in the quest for novel therapeutics.”
[Andrey Tarnovskiy, Sales Director, Europe at Enamine] “This year the size of Enamine’s REAL Space has reached tremendous 36 Billion compounds. We are excited to cooperate with Nostrum Biodiscovery to complement the available suite of search tools for REAL Space exploration with brand-new AI-based solution for high-throughput virtual screening and hope that our synergy will allow to facilitate and strengthen the drug discovery efforts of our customers.”
About Nostrum Biodiscovery
Nostrum Biodiscovery is a spin-off from the Barcelona Supercomputing Center (BSC-CNS) and the Institute for Research in Biomedicine (IRB), two of the most recognized Spanish international research centers.
Nostrum Biodiscovery provide advanced technologies in Molecular Modelling, with two areas of focus : therapeutics, e.g. small molecules design, targeted protein degradation, antibodies, immunologics and nucleic acids, and bio-based chemistry as in enzyme engineering.
Nostrum Biodiscovery’s customer-tailored solutions are based on state-of-the-art proprietary and 3rd-party software, combined with the latest development on AI. We use best in-class Molecular Modeling for data augmentation and fine-tuning of dedicated machine-learning algorithms.
With a focus on efficiency, innovation, and accessibility, Nostrum Biodiscovery is committed to providing cutting-edge solutions to the global scientific community.
Headquartered in Kyiv, Ukraine, Enamine combines a CRO profile with production and multi-level supply of innovative screening libraries, novel building blocks, fragments, and comprehensive chemistry support in drug discovery services, such as organic synthesis, medicinal chemistry, biological screening, ADME-PK testing, and integrated discovery. The major assets of the company are a collection of 4 Million screening compounds backed with 36 Billion synthetically feasible analogs for hit follow-up, and dynamically growing catalog of 284,000 building blocks with 2,000 new building blocks synthesized each month, providing a major competitive advantage in custom library synthesis. Enamine offers collaborative expertise to exclusively design and supply libraries of novel organic compounds and building blocks.